GlassScriptPhysician profile
Adeyinka Adejumo
NPI 1275063893
$8,256.33
in general payments reported to CMS, 2019-2025
19 companies · $4,732 in 2025
The $4,732 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $219 · 2024: $3,305 · 2025: $4,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,681 · Food and Beverage: $3,485 · Grant: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,680.89 |
| Food and Beverage | $3,485.44 |
| Grant | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $6,153.57 | 2024-2025 | Overstitch Endoscopic Suturing System, Axios, Exalt Model D |
| Olympus Corporation of The Americas | $701.66 | 2025 | Single Use Biliary Balloon Dilator |
| Janssen Biotech, INC. | $421.82 | 2025 | Tremfya |
| Abbvie INC. | $327.24 | 2023-2025 | Viberzi, Linzess, Creon |
| Medtronic, INC. | $117.71 | 2025 | Nexpowder |
| Fujifilm Healthcare Americas Corporation | $75.00 | 2023 | |
| Qol Medical, LLC | $66.62 | 2023-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $65.76 | 2023-2024 | Dificid |
| Madrigal Pharmaceuticals | $63.77 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $45.73 | 2023-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $42.68 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $27.37 | 2024 | Omvoh |
| Olympus America INC. | $25.27 | 2025 | Endoclot Phs |
| Ipsen Biopharmaceuticals, INC | $23.92 | 2024 | Iqirvo |
| Pfizer INC. | $23.14 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.60 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.61 | 2023 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $16.86 | 2024 | |
| Erbe USA INC | $16.00 | 2025 | Vio3/Apc3/Erbejet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeyinka Adejumo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.